
1. pharmaceutics. 2020 sep 25;12(10). pii: e919. doi: 10.3390/pharmaceutics12100919.

interaction hydroxychloroquine pharmacokinetically important drug
transporters.

weiss j(1), bajraktari-sylejmani g(1), haefeli we(1).

author information: 
(1)department clinical pharmacology pharmacoepidemiology, heidelberg
university hospital, im neuenheimer feld 410, 69120 heidelberg, germany.

(1) background: hydroxychloroquine used treat malaria autoimmune
diseases, potential use covid-19 currently under
investigation. thus far, information interactions hydroxychloroquine with
drug transporters mediating drug-drug interactions limited. assessed the
inhibition important efflux (p-glycoprotein (p-gp), breast cancer resistance
protein (bcrp)) uptake transporters (organic anion transporting polypeptide
(oatp)-1b1, oatp1b3, oatp2b1) hydroxychloroquine, tested p-gp bcrp
substrate characteristics, evaluated induction pharmacokinetically
relevant genes regulated nuclear pregnane x (pxr) (cyp3a4, abcb1) aryl
hydrocarbon receptor (ahr) (cyp1a1, cyp1a2). (2) methods: transporter inhibition 
was evaluated transporter over-expressing cell lines using fluorescent probe
substrates. p-gp bcrp substrate characteristics assessed comparing
growth inhibition over-expressing parental cell lines. possible mrna
induction analysed ls180 cells quantitative real-time pcr. (3) results:
hydroxychloroquine inhibit bcrp oatps tested inhibited p-gp at
concentrations exceeding 10 Âµm. p-gp overexpressing cells 5.2-fold more
resistant hydroxychloroquine control cells stressing substrate
characteristics. hydroxychloroquine induce genes regulated pxr ahr.
(4) conclusions: first evidence hydroxychloroquine's interaction
potential drug transporters low, albeit bioavailability simultaneously
orally administered p-gp substrates might increased hydroxychloroquine.

doi: 10.3390/pharmaceutics12100919 
pmid: 32992777 

